Trial Profile
Multicenter, Open-label, Two-arm, Parallel-design, Repeat-dose Clinical Trial to Evaluate the PK, Safety, and Tolerability of Four Intramuscular Injections of Risperidone ISM® 75 mg, at 28 Day Intervals in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Acronyms PRISMA-2
- Sponsors Rovi
- 03 Nov 2017 Results published in the International Clinical Psychopharmacology
- 28 Jul 2016 Results from this trial were presented at the 24th European Congress of Psychiatry, according to a Rovi media release.
- 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov